We serve Chemical Name:tert-butyl N-[2-(bromomethyl)phenyl]carbamate CAS:166329-43-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![tert-butyl N-[2-(bromomethyl)phenyl]carbamate](https://a.dearchem.com/CAS2/166329-43-7.png)
Chemical Name:tert-butyl N-[2-(bromomethyl)phenyl]carbamate
CAS.NO:166329-43-7
Synonyms:2-Methyl-2-propanyl [2-(bromomethyl)phenyl]carbamate;2-bromomethyl-N-tert-butoxycarbonylaniline;Carbamic acid, N-[2-(bromomethyl)phenyl]-, 1,1-dimethylethyl ester
Molecular Formula:C12H16BrNO2
Molecular Weight:286.165
HS Code:2924299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:309.0±25.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.576
PSA:41.82000
Exact Mass:285.036438
LogP:3.70
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Methyl-2-propanyl [2-(bromomethyl)phenyl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Carbamic acid, N-[2-(bromomethyl)phenyl]-, 1,1-dimethylethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-bromomethyl-N-tert-butoxycarbonylaniline Use and application,2-Methyl-2-propanyl [2-(bromomethyl)phenyl]carbamate technical grade,usp/ep/jp grade.
Related News: After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. 4,6-dichloro-2-methylpyridazin-3-one manufacturers Stem cell transplants from matched, related donors can be effective, but most patients don’t have such donors available to them. 1-hydroperoxy-7-tetraoxidaneyl-14,23,33,43,54,73,104-hexaoxino[6,1]hexaoxine suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. chlorhydrate de (pyridyl-2)-thio-2 imidazole vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. chlorhydrate de (pyridyl-2)-thio-2 imidazole vendor & factory.
